Aisling Capital — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital ManagementTaiho Ventures, LLC+3 more
Forge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure.
Advanced ManufacturingBiotechHealthtechMedical DevicesGrove City, US
Timothy J. Miller(Executive Officer, Director)in
BoardChris Garabedian(Director)inMolly McCartin(Director)in
Co-investorsDrive CapitalRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.